News articles about Novartis AG (NYSE:NVS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novartis AG earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.2711471415975 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- What’s In The Cards For Novartis This Earnings Season? (benzinga.com)
- FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy (finance.yahoo.com)
- Novartis to shut U.S. generics plant, cut 450 jobs (finance.yahoo.com)
- $1.25 EPS Expected for Novartis AG (NVS) This Quarter (americanbankingnews.com)
- FDA OKs 2nd gene therapy for blood cancer; 1st for adults (marketbeat.com)
Novartis AG (NYSE:NVS) opened at 86.16 on Friday. Novartis AG has a 12-month low of $66.93 and a 12-month high of $86.90. The firm has a 50-day moving average price of $85.56 and a 200-day moving average price of $82.13. The company has a market cap of $201.86 billion, a P/E ratio of 31.46 and a beta of 0.73.
Novartis AG (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.06. The firm had revenue of $12.24 billion during the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.23 EPS. On average, equities research analysts forecast that Novartis AG will post $4.75 earnings per share for the current fiscal year.
NVS has been the subject of a number of research analyst reports. Zacks Investment Research raised Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a research note on Tuesday, September 19th. Barclays PLC raised Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd. Cowen and Company set a $77.00 price target on Novartis AG and gave the stock a “hold” rating in a research note on Tuesday, July 11th. BidaskClub raised Novartis AG from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $83.00 price objective on shares of Novartis AG in a report on Thursday, June 22nd. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $84.13.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.